Plain-English translation of NCT06488378 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called combined with an FDA-approved drug called in people with advanced breast cancer that has specific genetic mutations (BRCA1, BRCA2, or PALB2). has never been approved by the FDA before, but is already an established, standard treatment for this type of cancer. Researchers want to find out if combining these two medications is safe and well-tolerated.
is already helping some patients with these genetic mutations, but not everyone responds well enough. This trial explores whether adding the new treatment can improve outcomes for people whose cancer is advanced and has spread to other parts of the body.
You likely qualify if…
You likely don't qualify if…
You will start by taking alone for 2 weeks, then begin taking both medications together in 28-day cycles. During the first two cycles, you'll have tumor biopsies on specific days to help researchers understand how the medications are working. You'll have imaging scans every 8 weeks and blood tests regularly. After treatment ends, you'll return for follow-up visits every 6 months for up to 3 years. The entire study participation is expected to last as long as the treatment is helping you, with potential follow-up extending to 3 years.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States